Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Proposed [GID-TA10667] Expected publication date: TBC
Search results
138 results
-
-
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
Proposed [GID-TA10599] Expected publication date: TBC
-
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Proposed [GID-TA10604] Expected publication date: TBC
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Proposed [GID-TA10668] Expected publication date: TBC
-
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
Proposed [GID-TA10637] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Proposed [GID-TA10638] Expected publication date: TBC
-
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)
Proposed [GID-TA10279] Expected publication date: TBC
-
Tocilizumab for treating systemic sclerosis (ID1396)
Proposed [GID-TA10346] Expected publication date: TBC
-
Intravenous zanamivir for treating influenza in hospital [ID1196]
Proposed [GID-TA10298] Expected publication date: TBC
-
Icosapent ethyl for reducing the risk of cardiovascular events due to hypertriglyceridemia [ID3831]
Proposed [GID-TA10736] Expected publication date: TBC
-
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]
Proposed [GID-TA10753] Expected publication date: TBC
-
Remdesivir for treating COVID-19 [ID3808]
Proposed [GID-TA10721] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Proposed [GID-TA10716] Expected publication date: TBC
-
Mepolizumab for treating hypereosinophilic syndrome [ID3749]
Proposed [GID-TA10755] Expected publication date: TBC
-
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]
Proposed [GID-TA10654] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
Proposed [GID-TA10714] Expected publication date: TBC
-
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Proposed [GID-TA10727] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Proposed [GID-TA10728] Expected publication date: TBC
-
Amivantamab for non-small cell lung cancer [ID3836]
Proposed [GID-TA10729] Expected publication date: TBC
-
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
Proposed [GID-TA10730] Expected publication date: TBC
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Proposed [GID-TA10700] Expected publication date: TBC
-
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]
Proposed [GID-TA10658] Expected publication date: 20 October 2021
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Proposed [GID-TA10536] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Proposed [GID-TA10757] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Proposed [GID-TA10758] Expected publication date: TBC
-
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
Proposed [GID-TA10706] Expected publication date: TBC
-
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]
Proposed [GID-TA10701] Expected publication date: TBC
-
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]
Proposed [GID-TA10739] Expected publication date: TBC
-
Sotagliflozin for treating type 2 diabetes [ID1657]
Proposed [GID-TA10665] Expected publication date: TBC
-
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Proposed [GID-TA10598] Expected publication date: TBC
-
Odevixibat (A 4250) for progressive familial intrahepatic cholestasis [ID1570]
Proposed [GID-TA10704] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously treated EGFR-positive metastatic non-small-cell lung cancer [ID3873]
Proposed [GID-TA10766] Expected publication date: TBC
-
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]
Proposed [GID-TA10767] Expected publication date: TBC
-
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]
Proposed [GID-TA10768] Expected publication date: TBC
-
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]
Proposed [GID-TA10770] Expected publication date: TBC
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
Proposed [GID-TA10771] Expected publication date: TBC
-
Foscarbidopa–foslevodopa for treating motor fluctuations in Parkinson's disease [ID3876]
Proposed [GID-TA10772] Expected publication date: TBC
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Proposed [GID-TA10773] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
Proposed [GID-TA10775] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Proposed [GID-TA10776] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Proposed [GID-TA10778] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Proposed [GID-TA10779] Expected publication date: TBC
-
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]
Proposed [GID-TA10600] Expected publication date: TBC
-
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]
Proposed [GID-TA10737] Expected publication date: TBC
-
Avatrombopag for treating chronic immune thrombocytopenia [ID3838]
Proposed [GID-TA10738] Expected publication date: TBC
-
Ozanimod for treating moderate to severe ulcerative colitis [ID3841]
Proposed [GID-TA10732] Expected publication date: TBC
-
Upadacitinib for treating active ankylosing spondylitis [ID3848]
Proposed [GID-TA10735] Expected publication date: TBC
-
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]
Proposed [GID-TA10740] Expected publication date: TBC